Ipsen Buying Memo Therapeutics For Up To $800M
French drugmaker Ipsen said Wednesday it has agreed to acquire Swiss biotechnology company Memo Therapeutics AG in a deal that could be worth more than €700 million ($796.6 million), expanding its...To view the full article, register now.
Already a subscriber? Click here to view full article